市場調查報告書
商品編碼
1417584
全球負壓傷口治療 (NPWT) 市場評估:按產品類型、傷口類型、最終用戶、地區、機會、預測(2017-2031 年)Negative Pressure Wound Therapy Market Assessment, By Product Type, By Wound Type, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
預計2023年全球負壓傷口治療(NPWT)市場規模將達23.1億美元,2031年將達34.9億美元,2023-2031年預測期內複合年增長率為5.28%。負壓傷口治療(NPWT)市場是全球先進傷口護理管理市場中成長最快的部分。這個市場的驅動因素是糖尿病和相關足部潰瘍盛行率的不斷上升、NPWT的持續技術進步和創新、包括潰瘍傷口、手術傷口和燒傷在內的傷口病例數量的增加,以及對負壓傷口治療的需求不斷增加。隨著需求的增加。糖尿病足潰瘍是糖尿病患者的一大擔憂,隨著糖尿病的流行,糖尿病足潰瘍患者的數量不斷增加,進一步推動了NPWT的需求。負壓傷口治療已被證明在短時間內管理和治療傷口方面非常有效,進一步推動了NPWT市場的需求。
此外,由於外科手術數量的增加和道路事故數量的增加,需要傷口治療的患者數量也在增加,進一步推動了全球負壓傷口治療(NPWT)市場的成長。然而,由於缺乏實施 NPWT 所需的熟練專業人員和技術專長以及設備成本高昂,該市場受到限制。
例如,2023年8月,專門生產醫用真空設備的瑞士公司Medela AG宣布推出名為 "Invia Integrated Dressing" 的新型一體化敷料產品,擴大其負壓傷口護理產品組合。該敷料於 2023 年 7 月獲得 FDA 批准,設計用於與 Medela 的 NPWT 幫浦、Liberty 和 Motion 搭配使用。這種一體式敷料是一種 "即貼即剝" 黏合劑,具有三層流體處理墊,包括親膚矽膠黏合邊框和快速連接器,易於操作。
糖尿病及其相關足部潰瘍的盛行率不斷上升,大大推動了負壓傷口治療(NPWT)市場的發展。糖尿病是一種與生活方式相關的疾病,伴隨多種併發症,其中糖尿病的主要併發症之一是足部潰瘍。糖尿病足潰瘍 (DFU) 是長期且控制不佳的糖尿病的常見且高度發病的後果,估計約 19-34% 的糖尿病患者一生中都會受到影響。NPWT 是治療糖尿病患者糖尿病足潰瘍的有效且經濟有效的方法。多項研究也支持負壓傷口治療可促進糖尿病足潰瘍的傷口有效癒合。例如,根據 2023 年 9 月發表在《Nature》雜誌上的一項研究,PRDX2(過氧化還原蛋白 2)透過其抗氧化作用促進 NHDF 增殖和遷移。它也被提議作為負壓傷口治療的機制,用於治療糖尿病足潰瘍等慢性傷口。
負壓傷口治療不斷發展的技術進步和創新將對市場產生積極影響。壓力設定範圍的最佳化、敷料黏附力的提高以及治療中使用的敷料的濕度控制等技術創新可能會推動 NPWT 的使用和需求,進一步推動市場成長。技術進步使 NPWT 設備更有效、更易於使用且更實惠,從而在醫院和家庭護理機構中得到越來越多的採用。市場進入者正在尋求利用創新解決方案來促進成長的機會。
例如,2023 年 4 月,3M 宣布其 Veraflo Cleanse Choice Complete 敷料和 Veraflo Cleanse Choice 敷料獲得 FDA 批准,該敷料可透過流體機械方式去除傷口中的感染性物質、非活性組織和傷口碎片。這可以改善肉芽形成並加速傷口癒合過程。除了 3M 的 Veraflow 產品組合(包括負壓傷口護理產品)之外,這些敷料也至關重要。
本報告研究分析了全球負壓傷口治療(NPWT)市場,提供市場規模和預測、市場動態、主要參與者趨勢和前景等。
Global negative pressure wound therapy (NPWT) market size was valued at USD 2.31 billion in 2023, and is expected to reach USD 3.49 billion in 2031, with a CAGR of 5.28% for the forecast period between 2023 and 2031F. The negative pressure wound therapy (NPWT) market is a fast-growing segment within the global advanced wound care management market. The market is driven by several factors, including the increasing prevalence of diabetes and associated foot ulcers, growing technological advancements and innovations in NPWT, growing cases of wounds including ulcers wounds, surgical and burn wounds, and growing demand for negative pressure wound therapies. Diabetes foot ulcer is a major concern for diabetic patients and with the increasing prevalence of diabetes, the diabetic foot ulcers patients are increasing, further driving the demand for NPWT. Negative pressure wound therapies have proven highly effective in managing and curing wounds in less time, further driving demand in the NPWT market.
Additionally, a growing number of surgical procedures and increasing cases of road accidents are leading to an increasing number of patients requiring wound care, further fueling the market growth for the global negative pressure wound therapy (NPWT) market. However, the lack of skilled professionals and technical expertise required for providing NPWT and the high cost of equipment are some of the restraints for the market.
For instance, in August 2023, Medela AG, a Swiss company specializing in medical vacuum devices, announced the expansion of its negative pressure wound therapy portfolio with a new integrated dressing product named 'Invia Integrated Dressing'. The dressing received FDA approval in July 2023 and is designed to work well with Medela NPWT pumps, Liberty, and MotionTM. The integrated dressing is a 'peel-and-stick' adhesive, having a three-layer fluid handling pad that contains a skin-friendly silicone adhesive border with a quick-connector for easy handling.
The growing prevalence of diabetes and associated foot ulcers significantly drives the negative pressure wound therapy (NPWT) market. Diabetes, being a lifestyle disorder, comes with several comorbidities, one of the major complications in diabetes is foot ulcers. Diabetic foot ulcers (DFU) are a common, highly morbid consequence of longstanding and poorly managed diabetes and are estimated to affect about 19-34% of diabetes patients in their lifetime. NPWT is an effective and cost-efficient method for managing diabetic foot ulcers in diabetic patients. Several research supports the fact that negative pressure wound therapy promotes efficient wound healing in diabetic foot ulcers. For instance, according to research published in Nature, in September 2023, PRDX2 (Peroxiredoxin 2) promotes NHDF proliferation and migration through its antioxidant properties, which is the proposed mechanism of negative pressure wound therapies for the treatment of chronic wounds like diabetic foot ulcers.
Growing technological advancements and innovations in negative pressure wound therapy positively impact the market. Several innovations like optimization of range of pressure settings, improved adhesive nature of dressing, and humidity management of dressings used in therapies are likely to promote the use and demand of NPWT, further fueling the market growth. Technological advancements make NPWT devices more effective, user-friendly, and affordable, thereby driving their adoption in both hospitals and home healthcare settings. Market players are dedicated to harnessing the opportunity to enhance their growth in the market through innovative solutions.
For instance, in April 2023, 3M announced that it received FDA approval for Veraflo Cleanse Choice Complete Dressing and Veraflo Cleanse Choice Dressing for hydromechanical removal of infectious materials, non-viable tissues, and wound debris from wounds, thus reducing the number of surgical debridement required. It will improve the granulation formation and speed up the wound healing process. These dressings are crucial in addition to 3M's Veraflow portfolio containing negative pressure wound therapy products.
Conventional negative pressure wound therapies include reusable components thus minimizing the wastage and saving resources. The segment is expected to gain traction from healthcare professionals and hospitals as the vacuum devices can be reused and dressing needs to be changed, thus saving effort and resources for repeated purchase. It provides better management of exudates from severe wounds, improving the wound-healing process. Despite the popularity of conventional NPWT, single-use negative pressure wound therapy segment is expected to grow faster owing to post-pandemic alertness.
With high investment in research and development activities, technological advancements by key players, and highly advanced healthcare infrastructure in North American countries like the United States and Canada, the region is expected to dominate the market with the highest value share. The supportive government initiatives for managing blood-related diseases are driving the growth of the market in the region. The high prevalence of diabetes and associated diabetic foot ulcers and other types of pressure ulcers in the region is contributing to the dominance of North America in the global negative pressure wound therapy market.
Market players are expanding their product offerings and giving their customers access to a wide range of cutting-edge and novel products. To gain market share, companies are expanding the range of products they offer. Industry participants use a variety of growth methods, including collaborations, mergers and acquisitions, product launches, and the development of new goods, to bolster their positions in the market.
In May 2023, Smith & Nephew plc announced that its PICO single-use negative pressure wound therapy systems have received an Innovative Technology contract from Vizient, Inc. The contract was given to Smith & Nephew plc, based on the recommendation of hospital experts who serve on one of Vizient's member-led councils. Innovative Technology program aims to improve clinical care and enhance the business model for health care organizations with potential products recommended by healthcare professionals.
All segments will be provided for all regions and countries covered:
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.